These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 15807716

  • 1. Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.
    Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas JG, Clotet B, Danise A, Landman R, Proll S, Snowden W, Foreman R, Smith P.
    HIV Med; 2005 Mar; 6(2):107-13. PubMed ID: 15807716
    [Abstract] [Full Text] [Related]

  • 2. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Mar; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 3. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F, Funk M, Linde R, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH, Wintergerst U.
    Eur J Med Res; 2002 Jul 24; 7(7):330-4. PubMed ID: 12176683
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P.
    Antivir Ther; 2003 Feb 24; 8(1):37-42. PubMed ID: 12713062
    [Abstract] [Full Text] [Related]

  • 5. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA.
    BMC Infect Dis; 2006 Jul 11; 6():107. PubMed ID: 16834769
    [Abstract] [Full Text] [Related]

  • 6. Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance.
    Brown LS, Kritz S, Chu M, Madray C.
    J Subst Abuse Treat; 2006 Jun 11; 30(4):331-5. PubMed ID: 16716848
    [Abstract] [Full Text] [Related]

  • 7. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May 11; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 8. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X, Peytavin G, Albert I, Bénoliel S, Ecobichon JL, Brun-Vézinet F, Mentré F, Leport C, Vildé JL.
    HIV Med; 2004 Jul 11; 5(4):307-13. PubMed ID: 15236622
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C, Burri M, Shen Y, Rode R, Nadal D, Pediatric Infectious Disease Group of Switzerland, Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Pediatr Infect Dis J; 2008 May 11; 27(5):431-7. PubMed ID: 18382386
    [Abstract] [Full Text] [Related]

  • 10. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
    Justesen US, Hansen IM, Andersen AB, Klitgaard NA, Black FT, Gerstoft J, Mathiesen LR, Pedersen C.
    HIV Med; 2005 Sep 11; 6(5):334-40. PubMed ID: 16156881
    [Abstract] [Full Text] [Related]

  • 11. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 11; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 12. Simplifying drug regimens.
    HIV Hotline; 1998 Mar 11; 8(1):11. PubMed ID: 11365353
    [Abstract] [Full Text] [Related]

  • 13. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JS.
    HIV Med; 2006 Jul 11; 7(5):311-6. PubMed ID: 16945076
    [Abstract] [Full Text] [Related]

  • 14. Indinavir, nelfinavir -- twice a day?
    TreatmentUpdate; 1998 Apr 11; 10(2):3-4. PubMed ID: 11365434
    [Abstract] [Full Text] [Related]

  • 15. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.
    AIDS; 2004 Jul 23; 18(11):1529-37. PubMed ID: 15238771
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
    Karlström O, Ståhle L, Perrin L, Tegude H, Sönnerborg A.
    Scand J Infect Dis; 2006 Jul 23; 38(5):371-4. PubMed ID: 16709540
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.